Skip to content

Author

S. Ravera

We have 4 of 326 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Potently neutralizing and protective human monoclonal antibodies against the measles fusion protein trimer.

Measles remains a significant source of morbidity and mortality globally. There are currently no licensed treatments for patients at high risk of severe disease. There is limited knowledge about the human antibody response to a measles infection or vaccination or the structural determinants of antibody-mediated neutral...

Laura S. Handal, E. Binshtein, Nurgun Kose et al. · 0 citations
Review Open access Oct 2026

Reprogramming the tumor microenvironment in mesothelioma: from immune suppression to therapeutic opportunity

Pleural mesothelioma (PM) is a rare and aggressive cancer with limited treatment options and poor prognosis. Unlike other thoracic cancers responding well to immunotherapy, PM typically lacks key predictive biomarkers such as Programmed Death-Ligand 1 (PD-L1) tumor expression. Nonetheless, immune checkpoint inhibitors...

L. Cerbone, Alessia Garau, Andrea Balossino et al. · 0 citations
Review Open access Aug 2026

RETHINKING AEROBIC METABOLISM IN RETINAL ROD OUTER SEGMENTS: TRIPLE METABOLIC HYPOTHESIS AND CLINICAL IMPLICATIONS.

A compartmentalized metabolic structure is proposed in which inner segment mitochondria, aerobic glycolysis, and a putative ectopic oxidative phosphorylation system in the outer segment in a triple metabolic mechanism, to supply their localized and divergent ATP demands.

R. Funk, M. Bruschi, L. Musante et al. · 0 citations
Aug 2026

Convergent IGHV3-53/3-66 antibodies elicited by Omicron BA.1 infection broadly neutralize emerging SARS-CoV-2 variants

G germline revertant analysis of the COV2-3731 mAb provided additional insights into how this COV2-3731 and other IGHV3-53/3-66-encoded public antibodies evolve to gain breadth against antigenically distinct SARS-CoV-2 variants such as BA.2.3.2, BA.3.1, KP.2.2, and, to some extent, KP.3.3.2.

Naveenchandra Suryadevara, Seth J. Zost, John M. Powers et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.